Get notified when CYCN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, indicating severe financial distress.
Cyclerion Therapeutics launches at-the-market offering of up to $2.99M, netting $2.7M
Filed May 7, 2025 · ~1 min read
Key Changes
-
high
Cyclerion is offering up to $2,994,080 of common stock via an at-the-market program with Guggenheim Securities, with no fixed price or number of shares.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $2.7 million, to be used for R&D, preclinical development, and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
New investors will suffer immediate dilution of $1.59 per share in net tangible book value, based on the assumed $3.05 offering price.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade CYCN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify